Prescribing overview
PromAce produces tranquilization and muscle relaxation and reduces anesthetic requirements. Oral and injectable labels differ.
Key prescribing checks
- Hypotension is an important risk, particularly in compromised patients and with other cardiovascular depressants.
- Review hydration, circulatory status and concurrent anesthetic or sedative medicines.
- The label warns against epinephrine for phenothiazine-associated hypotension because further blood-pressure reduction can occur; management belongs to the treating clinician.
- The injectable label warns against use with organophosphate products or procaine and in food-chain horses; male horses also require consideration of penile paralysis risk.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary label: tabletsTranquilization and preanesthetic use
Includes restraint for examinations and minor procedures.
Use / indication source ↗Dogs, cats and horses
US veterinary label: injectableTranquilization; species-specific procedural uses
Canine/feline label also includes motion-sickness vomiting and itching associated with skin irritation.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Central nervous system depression decreases spontaneous activity; other depressants and general anesthetics have additive effects.
Absorption, distribution, metabolism and elimination
Labels describe rapid action and hepatic detoxification, but do not provide species-specific quantitative half-lives.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
PromAce
US canine oral tablet label.
Contraindications · when not to use
- Do not use for organophosphate-poisoning tremors, with organophosphate dewormers or ectoparasiticides, or with procaine hydrochloride.
Precautions & monitoring
- Caution with cardiac disease, hypovolemia/shock, debilitation, liver dysfunction or leukopenia.
- Not for animals intended for human consumption.
PromAce Injectable
US injectable label for dogs, cats and horses.
Contraindications · when not to use
- Do not use for organophosphate-poisoning tremors, with organophosphate dewormers or ectoparasiticides, or with procaine hydrochloride.
Precautions & monitoring
- Caution with cardiac disease, hypovolemia/shock, debilitation, liver dysfunction or leukopenia.
- Rapid IV administration can cause cardiovascular collapse. Male horses risk penile paralysis; accidental intracarotid injection may be fatal. Not for food-chain horses.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Hypotension, prolonged depression or motor restlessness may occur; rare canine behavioral reactions include aggression.
Injectable precautions include penile paralysis in male horses and cardiovascular collapse with rapid IV administration.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsTranquilization/preanesthetic aidPromAce tablets | 0.25–1.0 mg/lb Oral · May repeat as required by veterinarian No fixed course specified | Labeled range, not a default individual prescription. Verify full dosing label ↗ |
| DogsLabeled tranquilization/procedural usesPromAce Injectable 10 mg/mL | 0.25–0.5 mg/lb IV, IM or SC · Individualized; no fixed interval specified Procedure-dependent | Give IV slowly; allow at least 15 minutes for full effect. Verify full dosing label ↗ |
| CatsLabeled tranquilization/procedural usesPromAce Injectable 10 mg/mL | 0.5–1 mg/lb IV, IM or SC · Individualized Procedure-dependent | Slow IV; allow at least 15 minutes. Verify full dosing label ↗ |
| HorsesTranquilization/procedural restraintPromAce Injectable 10 mg/mL | 2–4 mg/100 lb IV, IM or SC · Individualized Procedure-dependent | Slow IV; allow at least 15 minutes. Not for food-chain horses. Verify full dosing label ↗ |
Dose selection must consider cardiovascular status and other anesthetics; label ranges are not interchangeable between routes.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
PromAce
US canine oral tablet label.
- Other CNS depressants and anesthesia have additive effects; epinephrine is contraindicated for phenothiazine-related hypotension.
PromAce Injectable
US injectable label for dogs, cats and horses.
- Other CNS depressants and anesthesia have additive effects; epinephrine is contraindicated for phenothiazine-related hypotension.
Monitoring
Assess sedation, respiration, blood pressure and recovery.
Client counseling
Follow the exact prescription; unexpected agitation or marked depression warrants contact.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Use presentation-specific package storage and aseptic injection handling.
Brands, formulations & ingredient identity
Active ingredients
Acepromazine maleate
Other searchable names: ACP
Acepromazine maleate is the salt form of acepromazine.
PromAce tablets and injectable products are different presentations. Verify route and concentration rather than using brand recognition alone.
The cited tablet label is canine; the injectable label includes dogs, cats and horses. This difference matters when recording labeled species.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
PromAce
- Formulation
- Oral tablets
- Label / product scope
- Dogs
Tablet label specifies canine indications.
Product label / source ↗PromAce Injectable
- Formulation
- Injectable solution
- Label / product scope
- Dogs · Cats · Horses
Different presentation and species labeling from tablets.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →